溴隐亭在120例泌乳素水平正常的不孕症患者促排卵治疗中的辅助作用观察

目的:探讨溴隐亭在泌乳素水平正常的不孕症患者促排卵治疗中的辅助作用。方法:不孕症患者120例,以随机抽样法分为对照组(60例)与治疗组(60例)。对照组于月经周期第5 d开始口服枸橼酸氯米酚50 mg.d-1,共5 d;月经周期第9 d开始B超监测卵泡发育情况并测量子宫内膜厚度,当优势卵泡直径达到18 mm时,加用人绒毛膜促性腺激素10 000 IU诱发排卵。治疗组除上述治疗外于月经周期第1 d开始口服溴隐亭1.25 mg.d-1,若妊娠则停药,未妊娠则连续服用3个月。结果:对照组排卵期子宫内膜厚度平均为(7.3±1.7)mm,治疗组为(10.3±2.1)mm,差异有统计学意义(P<0.05)。对照组第1、2、3个月获得妊娠分别为6、4、4例,妊娠率为23%(14/60),先兆流产发生率为42%(6/14);治疗组第1、2、3个月获得妊娠分别为14、10、6例,妊娠率为50%(30/60),先兆流产发生率为26%(8/30),差异有统计学意义(P<0.05)。结论:溴隐亭联合枸橼酸氯米酚用于泌乳素水平正常的不孕症患者,可提高其妊娠率,疗效显著。     

溴隐亭治疗多囊卵巢综合征不育的临床观察

多囊卵巢综合征(PCOS)是妇科常见的内分泌紊乱疾病,育龄妇女患病率占5%~10%[1],是一种以慢性无排卵,卵巢多囊改变,高雄激素或胰岛素抵抗为特征的症侯群.是造成不育的主要原因.本院采用溴隐亭治疗多囊卵巢综合征,总结如下.     

溴隐亭治疗高泌乳素血症性无排卵141例分析

141例高泌乳素血症性无排卵患者服溴隐亭176例次。其中51例次加用了氯菧酚和/或绒毛促性腺激素。108例获妊娠共129例次。3例妊娠期出现鞍区压迫症状,再次服药者仅1例。流产、双胎、畸胎及宫内生长迟缓发生率皆不高。74例产后随诊2.9±1.5年。8例恢复排卵月经,但血泌乳素水平正常者仅3例。未发现病情加重者。本文提示了溴隐亭的高效、安全性及高泌乳素血症的良性病程。并认为疗效与个体对药物的敏感性有关。     

溴隐亭治疗高泌乳素血症

对32例高PRL血症采用以溴隐亭为主及其他辅助治疗的疗效进行分析。其结果:治疗后16周血清PRL值87%恢复正常;肿瘤组与非肿瘤组首次排卵所需溴隐亭用量及治疗周期数有显著性差异(P<0.01);本组排卵率81.2%,妊娠率62.1%,流产率22.7%,足月分娩9例,孕产期顺利,新生儿均无畸形。溴隐亭是治疗高PRL血症极为有效的药物,如及时辅助克罗米芬、HCG、HMG-HCG更可达到节省用药、缩短疗程、提高疗效的目的。     

溴隐亭在神经精神科临床的应用

溴隐亭(bromoeriptine)为麦角类的多巴胺(DA)激动剂,是一种新颖的神经内分泌药物。由于它可激动突触后的DA受体使DA功能加强,故临床上常用于治疗某     

溴隐亭治疗高催乳素血症致不孕不育l03例

高催乳素血症是一种下丘脑 -垂体 -性腺轴功能失调的疾病 ,主要症状为溢乳、闭经、头痛、头胀、视力障碍、不孕等。我院妇科内分泌不孕症门诊 ,自 1 995年元月～ 2 0 0 1年 1 2月 ,治疗不孕症病人 82 6例 ,经放射免疫催乳素值测定 ,其中高催乳素血症致不孕不育 1 0 3例 ,CT检查发现垂体肿瘤 6例 ,应用溴隐亭治疗 ,经临床观察疗效满意 ,现报告如下 :1　资料与方法1 1　一般资料　 1 0 3例病例中 ,年龄最小 2 5岁 ,最大 42岁 ,其中 2 5～ 3 0岁 6 5岁 ,占 6 3 % ;3 1～ 40岁3 3例 ,占 3 2 % ;41～ 42岁 5例 ,占 5 %。女性 1 0 2例 ,男性 1例…     

溴隐亭降糖作用的临床研究

目的:探讨溴隐亭的降糖作用及降糖机理。方法:用溴隐亭治疗38例糖尿病患者,服溴隐亭前后检测血糖、胰岛素及升糖激素浓度。结果:服溴隐亭后血糖显著降低(P<0.05) ,而胰岛素及升糖激素水平无显著变化。结论:溴隐亭对糖尿病人有明确的降糖作用,其降糖机理可能不是改变升糖激素水平     

溴隐亭治疗溢乳症5例

抗精神病药引起的溢乳症在精神科临床上颇为多见。本文报道溴隐亭治疗5例抗精神病药物引起的溢乳症,其中3例有显效,1例有进步,未发现有何副作用。     

溴隐亭治疗垂体催乳素瘤

目的；研究溴隐亭对垂体催乳素瘤的疗效。方法：垂体ＲＲＬ瘤病人１２例，ｐｏ溴隐亭２．５ｍｇ／ｄ，隔５ｄ递增２．５ｍｇ，递增至第１次出现排卵时的剂量，维持至第２个周期排卵为止，再每周递减２．５ｍｇ，至病人每周期有排卵月经时为最小维持量，连续治疗６ａ，结果，１２例病人全部恢复了有排卵月经，其中４例不孕病人妊娠并正常分娩。６ａ后ＣＴ复查，微腺瘤８例未增在，２例消失，２例腺瘤略有增大，结论：溴隐亭治疗１２例     

溴隐亭治疗异常溢乳合并无排卵（附36例分析）

报道３６例溴隐亭治疗的异常溢乳合并无排卵疗效。其中垂体溢乳素瘤１０例，剂量５－７．５ｍｇ／日，应用氯芪酚，ＨＣＧ辅助治疗３１例次，平均疗程７．１周。服药后血清ＰＲＬ恢复正常占５８．８２％，溢乳消通者占９４．４４％，８５．７％恢复排卵功能月经，１６例不孕妇女妊娠２０例次占６６．６７％。     

Chromosomal patterns of children born after induction of ovulation with bromocriptine

We investigated a possible influence of 2-bromo-alpha-ergocryptine (bromocriptine, CB 154) on the human foetus. The chromosome patterns of the children born to mothers treated with bromocriptine before conception and in early pregnancy were examined. In 19 children no numerical or structural chromosomal anomalies which might be ascribed to the use of bromocriptine could be demonstrated.     

促排卵周期性激素水平对排卵结局的影响

目的探讨促排卯周期中不同时期性激素水平对排卵结局的影响。方法选择自然周期有排卵障碍的患者使用克罗米芬（CC）＋绒促性素（HCG）促排,同时在月经周期的不同时间测定性激素促卵泡成熟激素（FSH）、黄体生成激素（LH）、雌二醇（E2）、孕酮（P）、垂体泌乳素（PRL）、睾酮（T）六项,最后观察患者的排卵结局。结果99例促排患者中正常排卵58例（58．6％）,为A组;发生卵泡未破裂黄素化综合征（LUFS）患者41例（41．4％）,为B组。两组患者年龄、不孕年限、体重、身高、体重指数（BMI）进行统计分析,差异无统计学意义（P〉0．05）。B组与A组比较：在月经第三日的E2和P、在月经第10日的FSH、在卵泡成熟日的LH均较低,差异有统计学意义（P〈0．05）。结论性激素在促排卵的结局中起到很重要的作用。     

二甲双胍在多囊卵巢综合征促排卵治疗中的作用分析

目的研究二甲双胍在多囊卵巢综合征促排卵治疗中的作用。方法选取2014年4月~2015年1月我院收治多囊卵巢综合征患者83例并随机分组,K组采用克罗米芬进行治疗,K+E组在K组基础上增加二甲双胍进行治疗。对比干预结果。结果 K+E组较之K组临床总有效率、妊娠率更高,干预后K+E组较之K组空腹血糖、空腹胰岛素、黄体生成素、性激素结合球蛋白、黄体生成素、促卵泡素、睾酮改善更显著(P0.05)。K+E组、K组药物不良反应发生率相似,均无严重不良反应发生(P0.05)。结论二甲双胍在多囊卵巢综合征促排卵治疗中的作用确切,值得推广。     

Genetic profile of SNP(s) and ovulation induction

Obtaining an adequate number of good quality oocytes while minimizing adverse drug reactions (ADRs) and cycle cancellation rates is considered the gold standard in controlled ovarian hyperstimulation (COH) for fertility treatment. Patients who undergo IVF/ICSI cycles tend to present with different responses to exogenous gonadotrophin administration. Research has shown that the secret probably lies in the various single nucleotide polymorhisms (SNPs) in their receptor genes. The decryption of human genome provided specialists with additional information in assessing and even predicting ovarian response to COH. In this context, the study of Pharmacogenomics, Pharmacogenetics and SNPs unravels as a promising field in optimizing fertility treatment. Several SNPs in FSH and estrogen receptor genes have been detected so far, but only three of them, one in FSH receptor and two in estrogen receptor genes have been associated with ovarian response to COH. It seems that the Asn/Ser variant of the FSH receptor functions more efficiently, while the Ser/Ser and Asn/Asn variants have a tendency to resist to FSH stimulation. With regards to estrogen receptor 1 (ESR1), the Pvull and the Xbal polymorphisms seem to be associated with differences in the response to ovarian stimulation, while the Rsal polymorphism in estrogen receptor 2 (ESR2) is currently under investigation. There exists evidence supporting the hypothesis that a set of genes, all related to the FSH hormone mechanism of action, may participate along with other factors to the control of ovarian response to FSH, thus a cautious interpretation of polymorphism detection results is considered mandatory. However, identifying potential genetic markers that could predict ovarian response and implementing them in routine screening tests for every woman entering an IVF/ICSI cycle, would be able to tailor fertility treatment to each patients needs thus maximizing the success rate and eliminating potential side-effects of fertility drugs.     

Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women

For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical mucous adverse effects that could prevent pregnancy in the face of successful ovulation. In addition, there is a significant risk of multiple pregnancies with clomifene compared with natural cycles. These drawbacks are mainly a result of the extended antiestrogenic effect of clomifene as a result of its accumulation in the body (clomifene isomers have a half-life of several days up to few weeks). Because of these problems, we proposed the concept of aromatase inhibition as a new method of ovulation induction that could avoid many of the adverse effects of clomifene. Over the last few years several published studies, both controlled and noncontrolled, compared clomifene and treatment with aromatase inhibitors (AIs), either alone or in combination with gonadotropins, for ovulation induction or augmentation. These studies found AIs as effective as clomifene in inducing ovulation, with the major advantage of absence of any antiestrogenic adverse effects. Several other major advantages of AIs include the lower serum estrogen production per developing follicle resulting in more physiological estrogen levels around the time of ovulation and good pregnancy rates with a lower incidence of multiple pregnancy than with clomifene. When combined with gonadotropins for assisted reproductive technologies, AIs reduce the dose of gonadotropins required for optimal follicle recruitment and improve the response to gonadotropin stimulation in poor responders. Such preliminary evidence suggests that AIs may replace clomifene in the future because of similar efficacy with a reduced adverse-effect profile. However, we believe that definitive studies in the form of randomised controlled trials comparing clomifene with AIs are needed.     

来曲唑与克罗米芬诱导排卵的临床效果比较

目的比较来曲唑与克罗米芬诱导排卵的临床效果。方法选择新疆维吾尔自治区人民医院符合标准的不孕症患者105例,完全随机分为来曲唑组（42例,口服来曲唑5mg／d,连用5d）和克罗米芬组（63例,口服用克罗米芬50mg／d,连用5d）。观察2组患者卵泡发育、子宫内膜生长情况,同时记录妊娠例数、流产例数、异位妊娠例数和继续妊娠。结果来曲唑组与克罗米芬组相比,人绒毛膜促性腺激素注射日≥14mm卵泡数明显减少,子宫内膜厚度较厚;2组均无卵巢过度刺激综合征的发生;来曲唑组妊娠率和继续妊娠率分别为21．4％（9／24）、14．3（6／42）,均高于克罗米芬组的12．7％（8／63）和6．3％（4／63）,但差异无统计学意义（P〉0．05）。结论来曲唑有类似克罗米芬的促排卵作用及相似的妊娠率,但来曲唑能否替代克罗米芬成为第一线诱导排卵药物,还需要多中心、大样本的临床研究。